Claims
- 1. A method of treating leukemia susceptible to treatment in an animal comprising the step of administering to the animal a pharmaceutically acceptable carrier and a safe and effective amount of a compound of the Formula I
5
- 2. A method of inhibiting the proliferation of leukemic cells in vitro, in vivo or ex vivo comprising the step of treating said cells with an effective amount of the compound of the Formula I,
6
- 3. A method of inhibiting the growth of leukemic cells in vitro, in vivo or ex vivo comprising the step of treating said cells with an effective amount of the compound of the Formula I,
7
- 4. A method of extending the life span of an animal having leukemia comprising the step of administering to the animal an effective amount of the compound of the Formula I,
8
- 5. A method according to claim 1, wherein R1 is an alkyl group of less than 7 carbon atoms
- 6. A method according to claim 2, wherein R1 is an alkyl group of less than 7 carbon atoms.
- 7. A method according to claim 3, wherein R1 is an alkyl group of less than 7 carbon atoms.
- 8. A method according to claim 4, wherein R1 is an alkyl group of less than 7 carbon atoms.
- 9. A method according to claim 1, wherein R is an alkyl of from 1 to 8 carbon atoms, and R1 is methyl, ethyl or isopropyl.
- 10. A method according to claim 2, wherein R is an alkyl of from 1 to 8 carbon atoms, and R1 is methyl, ethyl or isopropyl.
- 11. A method according to claim 3, wherein R is an alkyl of from 1 to 8 carbon atoms, and R1 is methyl, ethyl or isopropyl.
- 12. A method according to claim 4, wherein R is an alkyl of from 1 to 8 carbon atoms, and R1 is methyl, ethyl or isopropyl.
- 13. A method according to claim 1, wherein Y is chloro and X is hydrogen.
- 14. A method according to claim 1, wherein the compound of the Formula I is selected from the group consisting of 2-(4-thiazolyl)benzimidazole and 2-(methoxycarbonylamino)benzimidzole.
- 15. A method according to claim 2, wherein the compound of the Formula I is selected from the group consisting of 2-(4-thiazolyl)benzimidazole and 2-(methoxycarbonylamino)benzimidzole.
- 16. A method according to claim 3, wherein the compound of the Formula I is selected from the group consisting of 2-(4-thiazolyl)benzimidazole and 2-(methoxycarbonylamino)benzimidzole.
- 17. A method according to claim 4, wherein the compound of the Formula I is selected from the group consisting of 2-(4-thiazolyl)benzimidazole and 2-(methoxycarbonylamino)benzimidzole.
- 18. A method according to claim 1, further comprising the step of administering to said animal an effective amount of one or more of a potentiator or a chemotherapeutic agent.
- 19. A method according to claim 2, further comprising the step of administering to said animal an effective amount of one or more of a potentiator or a chemotherapeutic agent.
- 20. A method according to claim 18, wherein said potentiator is selected from the group consisting of procodazole; triprolidine; macrophage colony-stimulating factor (M-CSF); 7-thia-8-oxoguanosine; 6-mercaptopurine and vitamin A (retinol).
- 21. A method according to claim 18, wherein said chemotherapeutic agent is selected from the group consisting of a-interferon; interleukin-2; cytarabine and mitoxantrone; cytarabine and daunorubicin and 6-thioguanine; cyclophosphamide and 2-chloro-2′-deoxyadenosine; VP-16 and cytarabine and idorubicin or mitoxantrone; fludarabine and cytarabine and g-CSF; chlorambucil; cyclophosphamide and vincristine and (prednisolone or prednisone) and optionally doxorubicin; tyrosine kinase inhibitor; an antibody; glutamine; clofibric acid; all-trans retinoic acid; ginseng diyne analog; KRN8602 (anthracycline drug); temozolomide and poly(ADP-ribose) polymerase inhibitors; lysofylline; cytosine arabinoside; chlythorax and elemental enteral diet enriched with medium-chain triglycerides; amifostine; gilvusmycin; and a hot water extract of the bark of Acer nikoense.
- 22. A method according to claim 3, further comprising the step of treating said cells with an effective amount of one or more of a potentiator or a chemotherapeutic agent.
- 23. A method according to claim 22, wherein said potentiator is selected from the group consisting of procodazole; triprolidine; macrophage colony-stimulating factor (M-CSF); 7-thia-8-oxoguanosine; 6-mercaptopurine and vitamin A (retinol).
- 24. A method according to claim 22, wherein said chemotherapeutic agent is selected from the group consisting of a-interferon; interleukin-2; cytarabine and mitoxantrone; cytarabine and daunorubicin and 6-thioguanine; cyclophosphamide and 2-chloro-2′-deoxyadenosine; VP-16 and cytarabine and idorubicin or mitoxantrone; fludarabine and cytarabine and g-CSF; chlorambucil; cyclophosphamide and vincristine and (prednisolone or prednisone) and optionally doxorubicin; tyrosine kinase inhibitor; an antibody; glutamine; clofibric acid; all-trans retinoic acid; ginseng diyne analog; KRN8602 (anthracycline drug); temozolomide and poly(ADP-ribose) polymerase inhibitors; lysofylline; cytosine arabinoside; chlythorax and elemental enteral diet to enriched with medium-chain triglycerides; amifostine; gilvusmycin; and a hot water extract of the bark of Acer nikoense.
Parent Case Info
[0001] This is a continuation in part application of application Ser. No. 08/910,801 filed Aug. 12, 1997, which is a continuation of application Ser. No. 08/473,817 filed on Jun. 7, 1995.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09375173 |
Aug 1999 |
US |
Child |
09792112 |
Feb 2001 |
US |
Parent |
08473817 |
Jun 1995 |
US |
Child |
08910801 |
Aug 1997 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08910801 |
Aug 1997 |
US |
Child |
09375173 |
Aug 1999 |
US |